Jury Still Out on Cardiovascular Safety of Testosterone - Medscape
6/9/2022 12:00:00 AM2 years 11 months ago
by Marlene Busko
by Marlene Busko
A meta-analysis may provide some reassurance of the short-term cardiovascular safety of testosterone therapy for male hypogonadism until definitive 5-year TRAVERSE trial findings are available, expected in late 2022.
Despite a new meta-analysis claiming to show that testosterone replacement therapy for men with hypogonadism does not increase the risk of cardiovascular outcomes such as myocardial infarction or str… [+8632 chars]
full article...